{"contraindications":{"vaccineGroup":{"contraindication":[{"observationCode":"116","observationTitle":"Severe allergic reaction after previous dose of Meningococcal B","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Meningococcal B vaccine."},{"observationCode":"080","observationTitle":"Adverse reaction to vaccine component","contraindicationText":"Do not vaccinate if the patient has had an adverse reaction to a vaccine component."}]}},"series":[{"seriesName":"Meningococcal B risk 2-dose series MenB-4C Patient Seeks Protection","targetDisease":"Meningococcal B","vaccineGroup":"Meningococcal B","seriesType":"Risk","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"Yes","seriesGroupName":"Patient Seeks Protection","seriesGroup":"1","seriesPriority":"A","minAgeToStart":"10 years"},"indication":[{"observationCode":{"text":"Patient seeks protection","code":"001"},"description":"Administer to persons seeking protection.","beginAge":"16 years","endAge":"24 years","guidance":"A MenB vaccine series may be administered to adolescents and young adults to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16-18 years (recommendation Category B)."},{"observationCode":{"text":"Patient seeks Meningococcal B protection"},"description":"Administer to persons seeking protection from Meningococcal B.","beginAge":"16 years","endAge":"24 years","guidance":"A MenB vaccine series may be administered to adolescents and young adults to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16-18 years (recommendation Category B)."}]},{"seriesName":"Meningococcal B risk 2-dose series MenB-FHbp","targetDisease":"Meningococcal B","vaccineGroup":"Meningococcal B","seriesAdminGuidance":["A 2-dose series for MenB-FHbp (Trumenba) which is used only for healthy adolescents and young adults who are not at increased risk for meningococcal B disease."],"seriesType":"Risk","equivalentSeriesGroups":"2","selectSeries":{"defaultSeries":"No","productPath":"Yes","seriesGroupName":"Patient Seeks Protection","seriesGroup":"1","seriesPriority":"A","minAgeToStart":"16 years"},"indication":[{"observationCode":{"text":"Patient seeks protection","code":"001"},"description":"Administer to persons seeking protection.","beginAge":"16 years","endAge":"24 years","guidance":"A MenB vaccine series may be administered to adolescents and young adults to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16-18 years (recommendation Category B)."},{"observationCode":{"text":"Patient seeks Meningococcal B protection"},"description":"Administer to persons seeking protection from Meningococcal B.","beginAge":"16 years","endAge":"24 years","guidance":"A MenB vaccine series may be administered to adolescents and young adults to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16-18 years (recommendation Category B)."}]},{"seriesName":"Meningococcal B risk 2-dose series MenB-4C Increased Risk","targetDisease":"Meningococcal B","vaccineGroup":"Meningococcal B","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"Yes","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"10 years"},"indication":[{"observationCode":{"text":"Undergoing elective splenectomy","code":"002"},"description":"Administered to persons who are undergoing elective splenectomy if they have not previously received Meningococcal B vaccine. ","beginAge":"10 years","guidance":"Vaccination 14 or more days before splenectomy is suggested."},{"observationCode":{"text":"Microbiologists routinely exposed to Neisseria meningitidis","code":"050"},"description":"Administer to microbiologists routinely exposed to isolates of Neisseria meningitidis.","beginAge":"10 years"},{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk because of a serogroup B meningococcal disease outbreak","beginAge":"10 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons who have persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris).","beginAge":"10 years"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"10 years"}]},{"seriesName":"Meningococcal B risk 3-dose series MenB-FHbp Increased Risk","targetDisease":"Meningococcal B","vaccineGroup":"Meningococcal B","seriesType":"Risk","selectSeries":{"defaultSeries":"No","productPath":"Yes","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","minAgeToStart":"10 years"},"indication":[{"observationCode":{"text":"Undergoing elective splenectomy","code":"002"},"description":"Administered to persons who are undergoing elective splenectomy if they have not previously received Meningococcal B vaccine. ","beginAge":"10 years","guidance":"Vaccination 14 or more days before splenectomy is suggested."},{"observationCode":{"text":"Microbiologists routinely exposed to Neisseria meningitidis","code":"050"},"description":"Administer to microbiologists routinely exposed to isolates of Neisseria meningitidis.","beginAge":"10 years"},{"observationCode":{"text":"Persons at risk during an outbreak","code":"070"},"description":"Administer to persons identified as at increased risk because of a serogroup B meningococcal disease outbreak","beginAge":"10 years"},{"observationCode":{"text":"Persistent complement, properdin, or factor B deficiency","code":"151"},"description":"Administer to persons 10 years or older with persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris).","beginAge":"10 years"},{"observationCode":{"text":"Anatomical or functional asplenia","code":"160"},"description":"Administer to persons with anatomic or functional asplenia, including sickle cell disease.","beginAge":"10 years"}]}]}